After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback